Focus on Liver Cancer (HCC) Care
The COVID-19 Response Program for Patients features information tailored to the special needs of patients living with pediatric liver disease, rare liver disease, NASH, pre & post liver transplant, and liver cancer.
The effects of the novel coronavirus pandemic on liver patients’ ability to access non-COVID-19 related care have been broad and pervasive. The guidance for initiation of treatment and management for patients with viral hepatitis, transplant and cancer have been in flux during this unprecedented time of COVID for several months. In this update, I will focus on information for liver cancer patients and the efforts Global Institute is taking to help to define impactful, long term solutions.
Click here to view the full article.
We Need You in The Fight Against Liver Cancer, Join #OctoberIs4Livers 2021
October 13th 2021The GLI LIVE episode with Dr. Sharpless is the first #OctoberIs4Livers activity in a series of engaging and informative global activities taking place throughout the month of October to raise awareness about liver cancer and address the many disparities that exist with this disease.
Read More
The Need to Support the Restart of Liver Disease Medical Research and Public Health Programs
May 16th 2021Few liver health advocacy organizations have policy staff or personnel in Washington, DC. To fill this gap, we provide liver health policy updates to report on timely information and actionable updates on activities relevant to liver health, including liver cancer, viral hepatitis, autoimmune liver conditions as well as issues that span conditions, such as coverage or other policy decisions.
Read More
More Vaccines, Fewer Tests: Why COVID-19 Testing Remains Important
May 9th 2021The COVID-19 Response Program for Patients features information tailored to the special needs of patients living with pediatric liver disease, rare liver disease, NASH, pre/post liver transplant and liver cancer.
Read More
